Tarsons Products

Why is Tarsons Products Ltd falling/rising?

As of 28-Jul, Tarsons Products Ltd's stock price is at Rs 311.05, down 3.07%, with weak long-term fundamentals and declining investor participation contributing to its underperformance. The company has reported negative results for four consecutive quarters and a significant drop in institutional investor confidence.

As of 28-Jul, Tarsons Products Ltd's stock price is falling, currently at Rs 311.05, which reflects a decrease of Rs 9.85 or 3.07%. The stock has underperformed the sector by 3.06% today and reached an intraday low of Rs 306.9, marking a decline of 4.36%. This downward trend is further supported by a significant drop in investor participation, with delivery volume falling by 31.66% compared to the 5-day average.<BR><BR>The company's long-term fundamentals are weak, evidenced by a -39.98% compound annual growth rate (CAGR) in operating profits over the last five years and a return on equity (ROE) averaging only 6.24%. Additionally, the company has reported negative results for the last four consecutive quarters, with profit after tax (PAT) for the latest quarter falling by 24.3% compared to the previous four-quarter average. The return on capital employed (ROCE) is notably low at 4.44%, indicating poor profitability.<BR><BR>Institutional investor participation has also declined, with a reduction of 0.8% in their stake over the previous quarter, suggesting a lack of confidence in the company's prospects. This consistent underperformance is highlighted by the stock's -15.99% return over the past year, which is significantly worse than the benchmark BSE500, where the stock has underperformed in each of the last three annual periods.<BR><BR>Overall, the combination of weak financial performance, declining investor interest, and negative market sentiment contributes to the falling stock price of Tarsons Products Ltd.

Which are the latest news on Tarsons Products?

Should I buy, sell or hold Tarsons Products Ltd?

What does Tarsons Products do?

Tarsons Products Ltd, a micro-cap company in the healthcare services industry, reported net sales of ₹121 Cr and a net profit of ₹4 Cr for the quarter ending March 2026. The company, incorporated in 1983 and publicly listed since June 2021, has a market cap of ₹1,142 Cr.

Overview:<BR>Tarsons Products Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Tarsons Products Limited was incorporated in 1983 as Tarsons Products Private Limited and later converted to a Public Limited Company on June 14, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 121 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,142 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 73.00 <BR>Industry P/E: 36 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.58 <BR>Return on Equity: 2.37% <BR>Price to Book: 1.82 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Tarsons Products?

As of 10th June, Tarsons Products Ltd has a market capitalization of 1,142.00 Cr, with recent net sales of 422.51 Cr and a net profit of 14.32 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Tarsons Products Ltd has a market capitalization of 1,142.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 422.51 Cr, while the sum of Net Profit for the same period is 14.32 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 630.21 Cr, and Total Assets are valued at 1,080.04 Cr.

Who are in the management team of Tarsons Products?

The management team of Tarsons Products includes Sanjive Sehgal (Chairman & Managing Director), Rohan Sehgal (Whole-time Director), Gaurav Podar (Nominee), and independent directors Viresh Oberai, Sucharita Basu, and Girish Paman Vanvari, along with Santosh Kumar Agrawal (Chief Finance Officer & Company Secretary).

The management team of Tarsons Products includes the following individuals:<BR><BR>1. **Sanjive Sehgal** - Chairman & Managing Director<BR>2. **Rohan Sehgal** - Whole-time Director<BR>3. **Gaurav Podar** - Nominee<BR>4. **Viresh Oberai** - Independent Director<BR>5. **Sucharita Basu** - Independent Director<BR>6. **Girish Paman Vanvari** - Independent Director<BR>7. **Santosh Kumar Agrawal** - Chief Finance Officer & Company Secretary<BR><BR>If you need more details about their roles or contributions, feel free to ask!

Who are the peers of the Tarsons Products?

Tarsons Products' peers include Krsnaa Diagnostics, Suraksha Diagnostics, Laxmi Dental, One Global Services, 3B Blackbio, Health X Platform, and Hemant Surgical. In terms of management risk, growth, and capital structure, Tarsons Products ranks below average, with a 1-year return of -45.32%.

Peers: The peers of Tarsons Products are Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental, One Global Serv, 3B Blackbio, Health X Platfor, Hemant Surgical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suraksha Diagno. and Hemant Surgical, while Average management risk is found at Krsnaa Diagnost., Laxmi Dental, One Global Serv, 3B Blackbio, and the rest. Below Average management risk is noted for Tarsons Products and Health X Platfor. Growth is Good at Suraksha Diagno., Laxmi Dental, and Hemant Surgical, while Average growth is seen at Health X Platfor, and Below Average growth is noted for Krsnaa Diagnost., Tarsons Products, 3B Blackbio, and the rest. Excellent capital structure is present at Krsnaa Diagnost., Laxmi Dental, One Global Serv, and Health X Platfor, while Good capital structure is found at Tarsons Products and Hemant Surgical, and Excellent capital structure is noted for 3B Blackbio.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hemant Surgical at 278.57%, while the peer with the lowest is Laxmi Dental at -48.44%. Tarsons Products has a 1-year return of -45.32%, which is higher than Laxmi Dental but lower than Hemant Surgical. Additionally, Krsnaa Diagnost., Laxmi Dental, Tarsons Products, 3B Blackbio, and Health X Platfor all have negative six-month returns.

Are Tarsons Products Ltd latest results good or bad?

Tarsons Products Ltd's latest Q4 FY26 results show strong revenue growth of 7.31% year-on-year, reaching ₹120.93 crores; however, a significant 59.02% decline in net profit and shrinking margins indicate serious operational challenges, making the overall performance concerning.

Tarsons Products Ltd's latest results for Q4 FY26 present a mixed picture, but overall, they lean towards being concerning. The company achieved its highest-ever quarterly revenue of ₹120.93 crores, reflecting a year-on-year growth of 7.31% and a sequential increase of 12.09%. However, this revenue growth is overshadowed by a significant decline in net profit, which fell to ₹4.18 crores, marking a drastic 59.02% decrease compared to the same quarter last year.<BR><BR>Additionally, the operating margin has contracted sharply, declining by 451 basis points to 28.34%. The profit after tax (PAT) margin also decreased to 3.46%, down from 9.05% in Q4 FY25. This deterioration in profitability is attributed to rising operational costs, including a 21.19% increase in employee expenses and a 45.18% rise in depreciation, which have outpaced revenue growth.<BR><BR>Moreover, the reliance on other income, which constituted a significant portion of profit before tax, raises concerns about the sustainability of the reported profitability. The overall financial performance indicates that while revenue growth is positive, the underlying operational challenges and declining profit margins suggest a troubling trend for the company. <BR><BR>In summary, while Tarsons Products has shown strong revenue growth, the sharp decline in profitability and margins indicates significant operational pressures, making the latest results more negative than positive.

When is the next results date for Tarsons Products Ltd?

The next results date for Tarsons Products Ltd is 22 May 2026.

The next results date for Tarsons Products Ltd is scheduled for 22 May 2026.

Is Tarsons Products overvalued or undervalued?

As of December 1, 2025, Tarsons Products is considered overvalued with a PE ratio of 59.27, significantly higher than its peers, and has underperformed the market with a year-to-date return of -43.36%.

As of 1 December 2025, the valuation grade for Tarsons Products has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 59.27, an EV to EBIT of 40.66, and an EV to EBITDA of 13.33. These ratios suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Tarsons Products' PE ratio is significantly higher than that of Finolex Industries, which stands at 22.79, indicating a stark contrast in valuation. Additionally, while Tarsons Products has a PEG ratio of 0.00, this is not favorable when compared to peers like Shaily Engineers, which has a PEG of 0.83, suggesting that Tarsons may not be justifying its high valuation through growth. The company's recent stock performance has been poor, with a year-to-date return of -43.36%, contrasting sharply with the Sensex's 9.60% return, further reinforcing the notion of overvaluation.

How has been the historical performance of Tarsons Products?

Tarsons Products has shown strong sales growth from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, but profitability metrics, including profit before tax and profit after tax, have declined during the same period. Total assets increased significantly, while total debt rose sharply, indicating higher leverage.

Answer:<BR>The historical performance of Tarsons Products shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Tarsons Products has experienced notable changes in its financial performance from March 2021 to March 2025. Net sales increased from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, indicating a strong growth trajectory. However, the total operating income followed a similar trend, rising from 228.91 Cr to 392.41 Cr during the same period. The total expenditure also rose significantly, from 125.48 Cr in March 2021 to 281.69 Cr in March 2025. Operating profit (PBDIT) peaked at 161.16 Cr in March 2022 but decreased to 126.68 Cr by March 2025. Profit before tax saw a decline from 92.43 Cr in March 2021 to 44.80 Cr in March 2025, while profit after tax also dropped from 68.87 Cr to 29.77 Cr in the same timeframe. The company's total assets increased from 295.95 Cr in March 2021 to 1,080.04 Cr in March 2025, reflecting substantial growth in its asset base. Conversely, total debt rose from 3.27 Cr to 328.56 Cr, indicating a significant increase in leverage. Overall, while Tarsons Products has shown growth in sales and assets, profitability metrics have declined in recent years.

Is Tarsons Products technically bullish or bearish?

As of 18 August 2025, Tarsons Products has shifted to a bearish trend with moderate strength, indicated by bearish MACD and Bollinger Bands across multiple time frames, along with significant underperformance against the Sensex.

As of 18 August 2025, the technical trend for Tarsons Products has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish daily moving average. The KST is mildly bearish on the weekly and bearish on the monthly, while the Dow Theory shows no trend on the weekly and mildly bearish on the monthly. The stock has underperformed significantly against the Sensex over various periods, further supporting the bearish outlook.

Who are the top shareholders of the Tarsons Products?

The top shareholders of Tarsons Products include Sanjive Sehgal with 26.98%, Clear Vision Investment Holdings Pte Limited at 23.42%, and 16 Foreign Institutional Investors holding a combined 9.52%. Individual investors own 15.3% of the shares.

The top shareholders of Tarsons Products include the promoters, with Sanjive Sehgal holding the highest stake at 26.98%. Additionally, Clear Vision Investment Holdings Pte Limited is the largest public shareholder, owning 23.42%. The company also has 16 Foreign Institutional Investors (FIIs) holding a combined 9.52% of the shares. Individual investors collectively hold 15.3% of the company's shares.

Has Tarsons Products declared dividend?

Yes, Tarsons Products Ltd has declared a 100% dividend, amounting to ₹2 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating a decline in price performance despite the dividend declaration.

Tarsons Products Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.52%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.41%, the dividend return was 0%, resulting in a total return of -15.41%.<BR><BR>Over the past year, the price return was -8.35%, the dividend return was 0.47%, leading to a total return of -7.88%.<BR><BR>In the last 2 years, the price return was -33.53%, the dividend return was 0.35%, resulting in a total return of -33.18%.<BR><BR>For the 3-year period, the price return was -45.15%, the dividend return was 0.29%, culminating in a total return of -44.86%.<BR><BR>In the 4-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Tarsons Products has declared a dividend, the total returns over various periods indicate a negative trend in price performance, with minimal contributions from dividends.